Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glofitamab dose-escalation and expansion study in relapsed/refractory B-cell non-Hodgkin lymphoma
2023-505625-14-00Phase 2Authorised
- Sponsor
- Roche
- Start
- Jan 2017
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 13
01
Overview
Phase 2, open-label trial of glofitamab in mature B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and 5 more (2 arms), sponsored by Roche. Primary endpoints: Incidence of dose-limiting toxicities, Primary safety endpoints and 11 more. Planned start Jan 2017; status: authorised.
02
Drugs
glofitamab
03
Conditions
mature B-cell lymphomadiffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)mantle cell lymphoma (MCL)marginal zone B-cell lymphoma (MZL)
Beyond the preview
Go deeper on 2023-505625-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505625-14-00.